🇺🇸 FDA
Patent

US 11000513

Anhydrous compositions of mTOR inhibitors and methods of use

granted A61KA61K31/436A61K31/5377

Quick answer

US patent 11000513 (Anhydrous compositions of mTOR inhibitors and methods of use) held by PALVELLA THERAPEUTICS, INC. expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PALVELLA THERAPEUTICS, INC.
Grant date
Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/436, A61K31/5377, A61K45/06, A61K47/10